TY - JOUR
T1 - Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level
T2 - A self-controlled prospective study
AU - Gelfand, Joel M.
AU - Rudikoff, Donald
AU - Lebwohl, Mark
AU - Klotman, Mary E.
PY - 1998/8
Y1 - 1998/8
N2 - Objective: To study the plasma human immunodeficiency virus type 1 (HIV- 1) RNA levels of 12 patients seropositive for HIV who were undergoing UV-B phototherapy to determine if UV-B phototherapy upregulates HIV activity in humans. Design: A self-controlled prospective cohort of HIV-infected patients seen for the treatment of a skin disorder responsive to UV-B phototherapy. Viral levels were measured weekly for 8 weeks of phototherapy. Follow-up viral levels were measured for patients who continued phototherapy beyond 8 weeks, those who had a significant change in their viral level, or both. Setting: Outpatient clinic of an academic hospital. Patient: Patients with HIV disease and a skin disorder responsive to UV-B phototherapy. Inclusion criteria for patients in this study were those receiving a stable antiviral regimen for at least 6 weeks and who had no major illness or immunization in the 2 months before starting phototherapy. Of 72 patient volunteers screened, 15 met the criteria, 2 declined to participate, and 13 entered the study. One patient was dropped from the study because an accurate baseline measurement could not be obtained. Twelve patients were analyzed, 2 of whom left the study early, 1 at 6 weeks and 1 at 7 weeks. Interventions: Ultraviolet-B phototherapy. Main Outcome Measure: Plasma HIV-1 RNA viral level. Results: Plasma HIV-1 RNA levels showed no significant increase or decrease in most of the patients, defined as a 3-fold change from baseline (mean fold change from baseline after 8 weeks of phototherapy, -1.1; 95% confidence interval, 2.9 to - 5.0). Trend analysis indicated no significant pattern of change in viral levels (slope,-0.013 log; P>.25). The CD4+ cell counts also remained unchanged (mean before therapy, 277 X 109/L; mean after therapy, 285 X 109/L; P = .67). Conclusion: No significant effect of UV-B exposure was seen on plasma HIV-1 levels.
AB - Objective: To study the plasma human immunodeficiency virus type 1 (HIV- 1) RNA levels of 12 patients seropositive for HIV who were undergoing UV-B phototherapy to determine if UV-B phototherapy upregulates HIV activity in humans. Design: A self-controlled prospective cohort of HIV-infected patients seen for the treatment of a skin disorder responsive to UV-B phototherapy. Viral levels were measured weekly for 8 weeks of phototherapy. Follow-up viral levels were measured for patients who continued phototherapy beyond 8 weeks, those who had a significant change in their viral level, or both. Setting: Outpatient clinic of an academic hospital. Patient: Patients with HIV disease and a skin disorder responsive to UV-B phototherapy. Inclusion criteria for patients in this study were those receiving a stable antiviral regimen for at least 6 weeks and who had no major illness or immunization in the 2 months before starting phototherapy. Of 72 patient volunteers screened, 15 met the criteria, 2 declined to participate, and 13 entered the study. One patient was dropped from the study because an accurate baseline measurement could not be obtained. Twelve patients were analyzed, 2 of whom left the study early, 1 at 6 weeks and 1 at 7 weeks. Interventions: Ultraviolet-B phototherapy. Main Outcome Measure: Plasma HIV-1 RNA viral level. Results: Plasma HIV-1 RNA levels showed no significant increase or decrease in most of the patients, defined as a 3-fold change from baseline (mean fold change from baseline after 8 weeks of phototherapy, -1.1; 95% confidence interval, 2.9 to - 5.0). Trend analysis indicated no significant pattern of change in viral levels (slope,-0.013 log; P>.25). The CD4+ cell counts also remained unchanged (mean before therapy, 277 X 109/L; mean after therapy, 285 X 109/L; P = .67). Conclusion: No significant effect of UV-B exposure was seen on plasma HIV-1 levels.
UR - http://www.scopus.com/inward/record.url?scp=0031904775&partnerID=8YFLogxK
U2 - 10.1001/archderm.134.8.940
DO - 10.1001/archderm.134.8.940
M3 - Article
C2 - 9722723
AN - SCOPUS:0031904775
SN - 0003-987X
VL - 134
SP - 940
EP - 945
JO - Archives of Dermatology
JF - Archives of Dermatology
IS - 8
ER -